Geratherm Medical Past Earnings Performance

Past criteria checks 0/6

Geratherm Medical's earnings have been declining at an average annual rate of -14.5%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been declining at an average rate of 0.7% per year.

Key information

-14.5%

Earnings growth rate

-16.2%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-0.7%
Return on equity-4.7%
Net Margin-4.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Geratherm Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:GME Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2418-180
31 Mar 2420080
31 Dec 2322180
30 Sep 2324180
30 Jun 2326180
31 Mar 2326180
31 Dec 2226180
30 Sep 2225090
30 Jun 2224090
31 Mar 2224090
31 Dec 2125090
30 Sep 2127290
30 Jun 2127290
31 Mar 2129290
31 Dec 2028290
30 Sep 2025180
30 Jun 2024180
31 Mar 2020080
31 Dec 1920180
30 Sep 1922180
30 Jun 1922070
31 Mar 1923170
31 Dec 1822170
30 Sep 1821160
30 Jun 1821170
31 Mar 1820160
31 Dec 1721160
30 Sep 1722260
30 Jun 1721260
31 Mar 1722360
31 Dec 1622260
30 Sep 1622260
30 Jun 1623360
31 Mar 1622250
31 Dec 1522350
30 Sep 1521250
30 Jun 1521250
31 Mar 1520250
31 Dec 1419240
30 Sep 1418240
30 Jun 1417140
31 Mar 1416130
31 Dec 1317130

Quality Earnings: GME is currently unprofitable.

Growing Profit Margin: GME is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GME is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare GME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: GME has a negative Return on Equity (-4.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Geratherm Medical AG is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oliver Wojahnmwb research AG
IGOR KIMOddo Seydler
Enid OmerovicOddo Seydler